Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of Ad26.COV2.S dose levels and vaccination intervals in adults and adolescents
NL-OMON55105Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Janssen Pharmaceutical. Started Sep 2020; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON55105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55105.